Clinical utility of lipoprotein(a) and its related polygenic risk score in risk stratification of cardiovascular complications among Chinese patients with type 2 diabetes
Description: Biomarker discovery for diabetes cardiovascular complications can aid the development of preventive strategies and treatment tailored to the individual’s needs, thereby reducing residual cardiovascular risk. Recently, the 2022 European Atherosclerosis Society consensus statement suggests measurement of lipoprotein(a) [Lp(a)], a highly heritable biomarker, for atherosclerotic cardiovascular disease (CVD) risk assessment. Evidence from previous studies has also consistently demonstrated the causal and independent association between Lp(a) and CVD. However, it remains unclear whether measured Lp(a) or its associated genetic factors can provide comparable or additional prognostic information for prevention of CVD in type 2 diabetes (T2D). The Hong Kong Diabetes Biobank is a large multicentre prospective cohort study of patients with diabetes, with information on detailed clinical data, genotype data, baseline biochemistry measurements including routine lipids measured in a central laboratory, and blood samples for future biomarker measurements. In this project, we proposed to use this resource to measure the Lp(a) levels in Chinese patients with T2D (n = ~2000 individuals). This measurement together with our in-house GWAS and clinical data will be utilized to investigate the associations of Lp(a) levels and its related polygenic risk score with diabetes cardiovascular complications. We will further evaluate their prognostic value compared with established risk equations and/or other biomarkers, and estimate the population attributable fraction for CVD in T2D due to elevated Lp(a). Results generated from this project will help identify high risk patients for risk stratification and refine the current strategies of CVD risk assessment.
Funder: Health and Medical Research Fund
Amount: HKD 1,500,000
Funding type: grant
Funder scheme: HMRF - Advanced Medical Research
Start date: 2022-01-01
Investigator: Claudia Ha-ting TAM
Institution: Department of Medicine and Therapeutics, The Chinese University of Hong Kong
Funded outputs count: 0
Funder award ID: 11220296
OpenAlex ID: G8261336782